WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016054555) COMBINATION THERAPIES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/054555    International Application No.:    PCT/US2015/053799
Publication Date: 07.04.2016 International Filing Date: 02.10.2015
IPC:
A61K 31/00 (2006.01), A61K 39/395 (2006.01), A61P 35/00 (2006.01), C07K 16/28 (2006.01)
Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35 4056 Basel (CH).
CAO, Zhu, Alexander [US/US]; (US) (US only).
RONG, Xianhui [US/US]; (US) (US only).
PINZON-ORTIZ, Maria, Consuelo [US/US]; (US) (US only).
LONGMIRE, Tyler [US/US]; (US) (US only).
LEE, Benjamin, Hyun [US/US]; (US) (US only)
Inventors: CAO, Zhu, Alexander; (US).
RONG, Xianhui; (US).
PINZON-ORTIZ, Maria, Consuelo; (US).
LONGMIRE, Tyler; (US).
LEE, Benjamin, Hyun; (US)
Agent: COLLAZO, Diana, M.; (US)
Priority Data:
62/059,832 03.10.2014 US
Title (EN) COMBINATION THERAPIES
(FR) POLYTHÉRAPIES
Abstract: front page image
(EN)Combination therapies are disclosed. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders. The combination may comprise an immunomodulator and a second therapeutic agent, wherein: (i) the immunomodulator is an inhibitor of an immune checkpoint molecule chosen from the list of inhibitors of one or more of PD-1, PD L1, PD-L2, CTLA-4, TIM-3, LAG-3, CEACAM, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGFR beta, or the immunomodulator is an activator of a costimulatory molecule chosen from the list of agonists of one or more of OX40, CD2, CD27, CDS, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3 or CD83 ligand, and wherein (ii) the second therapeutic agent is chosen from one or more compounds as provided in Table 1, i.e. LCL 161, Rad-001 (Evrolimus), CGM097, LGH-447, LJM716 (Human monoclonal antibody), LBH589 (Panobinostat), INC424 (Ruxolitinib), BUW078 or BGJ398.
(FR)L'invention concerne des polythérapies. Les polythérapies peuvent être utilisées pour le traitement ou la prévention d'états et/ou de troubles cancéreux.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)